Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $137.55

Illumina, Inc. (NASDAQ:ILMN) has received a consensus rating of “Hold” from the twenty-one ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $137.55.

A number of equities research analysts recently commented on the company. Guggenheim dropped their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Canaccord Genuity Group reduced their price target on shares of Illumina from $115.00 to $92.00 and set a “hold” rating on the stock in a research report on Tuesday. TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and dropped their target price for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Morgan Stanley dropped their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Finally, Piper Sandler increased their price objective on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. Bank of Stockton lifted its stake in Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after acquiring an additional 80 shares in the last quarter. Stephens Inc. AR boosted its holdings in Illumina by 1.4% during the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after purchasing an additional 90 shares during the last quarter. Spire Wealth Management grew its position in Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after purchasing an additional 97 shares in the last quarter. IFP Advisors Inc increased its stake in Illumina by 19.1% in the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after buying an additional 99 shares during the last quarter. Finally, Freedom Investment Management Inc. lifted its position in Illumina by 3.7% during the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company’s stock worth $382,000 after buying an additional 101 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 1.8 %

Shares of ILMN opened at $77.88 on Wednesday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $80.07 and a two-hundred day moving average price of $115.86. The stock has a market cap of $12.33 billion, a price-to-earnings ratio of -10.14, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts predict that Illumina will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.